Physicians' Academy for Cardiovascular Education

PCSK9 antibody does not increase HbA1c, fasting glucose or diabetes risk

Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus

Literature - Sattar N, Toth PP, Blom DJ, et al. - American Journal of Cardiology 2017; published online ahead of print

Main results

Conclusion

In two open-label extension studies, treatment with evolocumab plus SOC for the duration of 1 year did not increase HbA1c, fasting glucose or diabetes risk in comparison to SOC alone. Participants in the evolocumab plus SOC group had a slight increase in weight, which was mainly driven by participants without diabetes or with a low risk for diabetes.

References

Show references

Find this article online at Am J Cardiol

Share this page with your colleagues and friends: